Drug Profile
Calcitonin oral transmucosal - Watson
Alternative Names: Calcitonin buccal - WatsonLatest Information Update: 10 Apr 2008
Price :
$50
*
At a glance
- Originator Watson Laboratories
- Class Neuropeptides; Peptide hormones
- Mechanism of Action Calcitonin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Postmenopausal osteoporosis
Most Recent Events
- 05 Feb 2003 No development reported - Preclinical for Postmenopausal osteoporosis in USA (Transmucosal)
- 16 Jan 2001 TheraTech is now called Watson Laboratories
- 23 Feb 1999 TheraTech is now a subsidiary of Watson Pharmaceuticals